Replicor Inc. is a Canadian biotechnology company focused on the development of its nucleic acid polymer (NAP) technology for the treatment of hepatitis B (HBV) and delta (HDV) infections.
NAPs are the only antiviral agent to directly target the immunosuppressive protein (HBsAg) which drives chronic HBV infection and liver disease. Our lead clinical NAP drug product is REP 2139-Mg, a proprietary formulation of REP 2139 which makes once weekly subcutaneous injections easily tolerated.
Replicor's latest clinical data demonstrates that NAP-based combination therapy can restore immune control of HBV infection in 78% of patients and eliminate HDV infection in 74% of patients. These effects persist in the absence of any therapy, allowing the liver to heal.
REP 2139-Mg based combination promises to revolutionize the therapy of chronic HBV and HDV infection and play a pivotal role in the WHO's goal of eliminating viral hepatitis by 2030.
Company Details
- Employees
- 6
- Address
- 6100 Avenue Royalmount, Montreal,quebec H4p 2r2,canada
- Phone
- 514.733.1998
- in****@****cor.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- replicor.com
- Keywords
- Toronto.
- HQ
- Montreal, Quebec
Replicor Inc. Questions
Replicor Inc.'s helpline number is 514.733.1998
Replicor Inc.'s website is replicor.com
Replicor Inc.'s LinkedIn profile is https://ca.linkedin.com/company/replicor-inc-
Replicor Inc. has
6 employees.
View email and phone details for 6
employees at Replicor Inc..
Replicor Inc.'s industry is
Biotechnology Research
Replicor Inc.'s top competitors are
Abnatura,
Inspire Biotherapeutics Inc,
Norcam Inc.,
Epitopea,
Forte Corp Holdings,
Cordex Biologics,
Labspace Studio,
Dalcor Pharmaceuticals,
Modulari-T Bio,
Thryv Therapeutics Inc..
Replicor Inc.'s support email address is info@replicor.com
Replicor Inc.'s categories are Biotechnology Research
